Prescient Therapeutics Ltd


Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 

View in Other Languages


Australian Market Report of February 14, 2011: Black Fire Minerals (ASX:BFE) To Acquire Tungsten/Copper Project in USA

🕔2/14/2011 12:20:00 PM 12455

Australian Market Report of February 14, 2011 includes: Black Fire Minerals Limited (ASX:BFE) is to acquire 100% of the advanced Pilot Mountain Tungsten-Copper Project in Nevada, USA; Virax Holdings Limited (ASX:VHL) is to develop a novel skin cancer product; Southern Cross Goldfields Limited (ASX:SXG) discovered near-surface high-grade gold deposits in Western Australia; Prosperity Resources Limited (ASX:PSP) commenced gold drilling in Indonesia.

Read Full Article

Virax Holdings Limited ASX: VHL - Commencement of Phase II US trials - Dr David Beames, CEO

🕔11/20/2006 9:19:00 AM 4000

Virax Holdings Limited (ASX: VHL) - Commencement of Phase II US trials - Dr David Beames, CEO; Boardroomradio is pleased to announce that Virax Holdings Limited (ASX: VHL) has published an audio file.

Read Full Article

Aegis Equities Research Announce Health and Life Science Review, August 2006

🕔8/15/2006 2:42:55 PM 13882

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.

Read Full Article


  • This Page Viewed: (Last 7 Days: 16) (Last 30 Days: 64) (Since Published: 12321) 

Company Data

  • (03) 9853 5134 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1986/12/19 
  • Homepage

More News Results

  • 2024/02/23: Appendix 4D and Half Year Financial Report*
*refer to company website